Lymphocyte apoptosis and its association with the inflammatory markers and disease severity in juvenile-onset systemic lupus erythematosus patients

Table 1 Baseline patients’ Features^a

	N = 100 (%)
*Clinical manifestations*
Arthritis	72 (72)
Secondary antiphospholipid syndrome	46 (46)
Nephritis	83 (83)
Serositis	29 (29)
Neuropsychiatric	26 (26)
Mucocutaneous	28 (28)
*Immune profile*
ANA	90 (90)
Anti-ds DNA	81 (81)
aPL	46 (46)
Leucopenia	48 (48)
Hypocomplementemia	50 (50)
*Disease activity and Disease damage at sampling visit*
SLEDAI-2 K [Median (IQR)]	10 (8)
SDI [Median (IQR)]	2 (2)
*Medications*
Glucocorticoids	100 (100)
Mycophenolate mofetil	17 (17)
Cyclophosphamide	15 (15)
Hydroxychloroquine	70 (70)
Azathioprine	33 (33)

Abbreviations: IQR interquartile range, ANA anti-nuclear antibodies, Anti-ds DNA anti-double stranded deoxyribonucleic acid antibodies, aPL antiphospholipid antibodies, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index-2 K, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index
^aUnless indicated, data are presented in number (N) and percentage

ISSN: 1546-0096